Catalyst
Slingshot members are tracking this event:
Alnylam to start a Phase 1 trial in mid-2016 for ALN-HBV, an investigational RNAi therapeutic targeting the hepatitis B viral (HBV) genome for the treatment of chronic HBV infection
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 07, 2016
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=978629
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Hepatitis B Viral Genome, Hbv, Hbv Infection, Phase 1 Trial, Aln-hbv, Rnai Therapeutic
